ImmuPharma的股份在周一在大量贸易中下跌了31.4%,没有公开说明理由。 ImmuPharma shares dropped 31.4% on Monday amid heavy trading, with no public reason given.

ImmumPharma (LON:IMM) 股份在星期一暴跌31.4%, ImmuPharma (LON:IMM) shares plunged 31.4% on Monday, closing at GBX 6.70 after a surge in trading volume to 27.3 million shares—242% above average. 股票交易低于50日和200日移动平均线, 之后GBX的收盘率为9.76%. The drop followed a previous close of GBX 9.76, with the stock trading below its 50-day and 200-day moving averages. 该公司是一家在伦敦上市的生物制药公司,开发百草枯自发免疫性疾病疗法,市场上限为3 368万英镑,P/E比率为负数。 The company, a London-listed biopharmaceutical firm developing peptide-based therapies for autoimmune diseases, has a market cap of £33.68 million and a negative P/E ratio. 其主要候选人P140(LupuzorTM)正在为狼疮开发。 Its lead candidate, P140 (Lupuzor™), is in development for lupus. 没有公开解释下降原因。 No public explanation for the decline was provided.